What is the difference between a primary and a metastatic brain tumour?

A primary brain tumour arises from cells of the central nervous system itself, such as a glioma from glial cells, whereas a metastatic brain tumour is a deposit of a cancer that originated elsewhere in the body and spread to the brain. Metastases are more common overall than primary brain tumours.

Why does modern classification use molecular markers?

Because molecular features such as IDH mutation status define tumour types more precisely and consistently than histology alone, the WHO classification now integrates molecular markers with microscopic appearance into a single diagnosis. This is a classification framework, not clinical guidance.

Brain Neoplasm

A brain neoplasm is an abnormal new growth of cells within the brain, arising either from cells of the central nervous system itself (primary tumours, such as gliomas) or from cancers elsewhere in the body that spread to the brain (metastases). Brain neoplasms span a wide spectrum of biological behaviour and are now classified by integrating histological and molecular features.

Definition

A brain neoplasm is a primary or metastatic tumour of the brain - a clonal proliferation of cells originating within central nervous system tissue or spreading to it - classified and graded according to integrated histopathological and molecular criteria.

Scope

The entry covers brain neoplasms as a neuropathological category: the distinction between primary and metastatic tumours, the major tumour families (notably gliomas), the concept of grading, and the integrated histological-and-molecular classification used in contemporary practice. It is a reference and educational overview and does not provide diagnostic or treatment recommendations.

Core questions

How do primary brain tumours differ from brain metastases in origin and behaviour?
What are the major families of primary brain tumours, and how are gliomas characterised?
How has classification shifted from purely histological grading to integrated molecular diagnosis?

Key concepts

Primary versus metastatic brain tumours
Gliomas and astrocytic tumours
Tumour grading
Integrated histological and molecular diagnosis
IDH mutation status
Infiltrative growth and mass effect
WHO classification of CNS tumours

Mechanisms

Brain neoplasms arise when cells acquire alterations that drive uncontrolled proliferation. Primary tumours originate from intrinsic central nervous system cell types - for example astrocytes and oligodendrocytes give rise to gliomas, the most common primary intra-axial brain tumours - while metastases derive from systemic cancers that reach the brain through the bloodstream. Tumours injure the brain not only by destroying and infiltrating tissue but also through mass effect, oedema, and raised intracranial pressure. Behaviour ranges from slow-growing, circumscribed lesions to highly infiltrative, aggressive tumours, and is summarised by grading. Contemporary classification, codified in successive WHO schemes, integrates histological appearance with molecular markers such as IDH mutation status to define tumour types more precisely than morphology alone.

Clinical relevance

Brain neoplasms can produce focal neurological deficits, seizures, and signs of raised intracranial pressure depending on their location and growth, and their pathological classification underlies how they are defined and prognosticated. This entry is provided for reference and education; it describes tumour pathology and classification and is not a source of diagnostic or treatment advice.

Epidemiology

Brain and other central nervous system tumours are a relatively uncommon but disproportionately serious category of neoplasm, contributing substantially to cancer-related neurological disability and mortality. Metastatic involvement of the brain is considerably more common than primary brain tumours overall.

Evidence & guidelines

The classification of brain tumours is governed by the WHO Classification of Tumors of the Central Nervous System, whose 2016 and 2021 editions formalised the integration of molecular markers with histology. Burden estimates draw on the Global Burden of Disease neurological-disorders analyses.

History

Brain tumour classification was historically based on the presumed cell of origin and microscopic appearance, with grading schemes used to summarise malignancy. The recognition of recurrent molecular alterations - exemplified by IDH mutations in gliomas - led the 2016 and 2021 WHO classifications to adopt an integrated diagnosis combining histology and molecular features.

Key figures

David N. Louis
Arie Perry

Seminal works

louis-2021
louis-2016

Frequently asked questions

What is the difference between a primary and a metastatic brain tumour?: A primary brain tumour arises from cells of the central nervous system itself, such as a glioma from glial cells, whereas a metastatic brain tumour is a deposit of a cancer that originated elsewhere in the body and spread to the brain. Metastases are more common overall than primary brain tumours.
Why does modern classification use molecular markers?: Because molecular features such as IDH mutation status define tumour types more precisely and consistently than histology alone, the WHO classification now integrates molecular markers with microscopic appearance into a single diagnosis. This is a classification framework, not clinical guidance.